



Form PTO-1449 (modified)		Atty. Docket No. DEBE:028US	Serial No. 10/743,697
Office of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Peter Kufer <i>et al.</i>	
		Filing Date: December 22, 2003	Group: <del>Unknown</del> 1644
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
PJH	B3	WO 01/040312	1/18/01	PCT			Abstract
↓	B4	WO 01/090190	11/29/01	PCT			English
↓	B5	WO 03/035694	5/01/03	PCT			English

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

25410044.1

EXAMINER: <i>[Signature]</i>	DATE CONSIDERED: 3/22/02
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

Form PTO-1449 (modified)

Atty. Docket No.  
DEBE:028USSerial No.  
10/743,697

List of Patents and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant  
Peter Kufer *et al.*Filing Date:  
December 22, 2003Group:  
Unknown 164fU.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
Pkt	A1	5,258,498	11/02/93	Huston and Oppermann	530	350	5/19/88
Pkt	A2	5,525,491	6/11/96	Huston <i>et al.</i>	435	69.7	6/09/94

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
Pkt	B1	EP 573 551	5/21/03	Europe			
Pkt	B2	EP 623 679	11/09/94	Europe			

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
Pkt	C1	Baynex, "Recombinant protein expression in Escherichia coli," <i>Curr. Opin. Biotech.</i> , 10:411-421, 1999.
	C2	Bohlen <i>et al.</i> , "Cytolysis of Leukemic B-cells by T-cells activated via two bispecific antibodies," <i>Cancer Res.</i> , 53:4310-4314, 1993.
	C3	Brühl, "Depletion of CCR5-expressing cells with bispecific antibodies and chemokine toxins: a new strategy in the treatment of chronic inflammatory diseases and HIV," <i>J. Immunol.</i> , 166:2420-2406, 2001.
	C4	Cortez-Retamozo <i>et al.</i> , "Efficient tumor targeting by single-domain antibody fragments of camels," <i>Int. J. Cancer</i> , 98:456-462, 2002.
	C5	Davies and Reichmann, "Antibody VH domains as small recognition units," <i>Biotechnology</i> , 13:475-479, 1995.
✓	C6	Davies and Riechmann, "Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability," <i>Protein Engineering</i> , 9(6):531-537, 1996.

25373241.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.  
DEBE:028USSerial No.  
10/743,697Applicant  
Peter Kufer *et al.*Filing Date:  
December 22, 2003Group:  
~~Unknown~~ 1644

U.S. Patent and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
Patt	C7	De Jonge <i>et al.</i> , "In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotypic) induces long-term survival in the murine BCL1 lymphoma model," <i>J. Immunol.</i> , 161:1454-1461, 1998.
	C8	Desmyter <i>et al.</i> , "Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody," <i>J. Biol. Chem.</i> , 276(28):26285-26290, 2001.
	C9	Destmyter <i>et al.</i> , "Three camelid VHH domains in complex with porcine pancreatic $\alpha$ -amylase," <i>J. Biol. Chem.</i> , 277(26):23645-23650, 2002.
	C10	Dumoulin <i>et al.</i> , "Single-domain antibody fragments with high conformational stability," <i>Protein Science</i> , 11:500-515, 2002.
	C11	Conrath <i>et al.</i> , "Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs," <i>J. Biol. Chem.</i> , 276(10):7346-7350, 2001.
	C12	Ewert <i>et al.</i> , "Biophysical properties of camelid VHH domains compared to those of human VH3 domains," <i>Biochemistry</i> , 41:3628-3636, 2002.
	C13	Harmsen <i>et al.</i> , "Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features," <i>Molecular Immunology</i> , 37:579-590, 2000.
	C14	Jobling <i>et al.</i> , "Immunomodulation of enzyme function in plants by single-domain antibody fragments," <i>Nature Biotech.</i> , 21:77-80, 2003.
	C15	Kufer <i>et al.</i> , "Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer," <i>Cancer Immunol. Immunother.</i> , 45:193-197, 1997.
	C16	Löffler <i>et al.</i> , "A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes," <i>Blood</i> , 95(6):2098-2103, 2000.
	C17	Mack <i>et al.</i> , "Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3," <i>J. Immunol.</i> , 158:3965-3970, 1997.
	C18	Mack <i>et al.</i> , "A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity," <i>Proc. Natl. Acad. Sci., USA</i> , 92:7021-7025, 1995.

25373241.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.  
DEBE:028USSerial No.  
10/743,697Applicant  
Peter Kufer *et al.*Filing Date:  
December 22, 2003Group:  
Unknown *1601*U.S. Patent Documents  
*See Page 1*Foreign Patent Documents  
*See Page 1*Other Art  
*See Page 1*

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>Pkt</i>	C19	Muruganandam <i>et al.</i> , "Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium," <i>FASEB Journal</i> , 16:240-242, 2002.
	C20	Muyldermans <i>et al.</i> , "Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains," <i>Trends in Biochemical Sciences</i> , 26(4):230-235, 2001.
	C21	Riechmann, "Rearrangement of the former VL interface in the solution structure of a camelised, single antibody VH domain," <i>J. Mol. Biol.</i> , 259:957-969, 1996.
	C22	Spinelli <i>et al.</i> , "Camelid heavy-chain variable domains provide efficient combining sites to haptens," <i>Biochemistry</i> , 39:1217-1222, 2000.
✓	C23	Tanha <i>et al.</i> , "Optimal design features of camelized human single-domain antibody libraries," <i>J. Biol. Chem.</i> , 276(27):24774-24780, 2001.

25373241.1

EXAMINER:

DATE CONSIDERED:

*3/22/06*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)